Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aura Biosciences Inc (NQ: AURA )

7.490 +0.240 (+3.31%)
Streaming Delayed Price Updated: 12:45 PM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aura Biosciences Inc

< Previous 1 2 Next >
Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium
From Aura Biosciences Inc.
Via Business Wire
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference
From Aura Biosciences, Inc.
Via Business Wire
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting
From Aura Biosciences
Via Business Wire
Aura Biosciences Announces Pricing of Initial Public Offering
From Aura Biosciences, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.